Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Forget Market Volatility With These Dividend Growth Stocks
by Sweta Killa
Zeroing in on companies that not only offer dividends but also consistently increase their payouts seems like a good idea.
Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.
Allscripts Completes Sale of EPSi Business to Strata
by Zacks Equity Research
Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.
Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus
by Zacks Equity Research
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the third quarter, Thermo Fisher (TMO) invests more than $140 million to increase the production of its laboratory plastic consumables.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $467.53, moving +0.17% from the previous trading session.
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands
by Zacks Equity Research
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Here's Why You Should Add AngioDynamics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Bruker Rides on Nano and MALDI Launches Despite Margin Debacle
by Zacks Equity Research
Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Veeva Develops 2 Applications on Veeva Clinical Network (Revised)
by Zacks Equity Research
This should boost Veeva's (VEEV) portfolio of cloud-based offerings for the life sciences industry.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
by Zacks Equity Research
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
NuVasive's (NUVA) MaXcess Retractor Study Results Positive
by Zacks Equity Research
NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Ecolab Introduces New Automated Precision Dispensing System
by Zacks Equity Research
Ecolab's (ECL) newly launched Precision Dispensing System for Membranes can drive productivity and boost worker safety.
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
by Zacks Equity Research
Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.